Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2014; 20(40): 14733-14746
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14733
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14733
Adjuvant therapy in pancreatic cancer
Owain Peris Jones, James Daniel Melling, Paula Ghaneh, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 5th Floor UCD Building, Daulby Street, Liverpool L69 3GA, United Kingdom
Author contributions: All three authors contributed to the literature search, writing and editing of this manuscript.
Correspondence to: Paula Ghaneh, Professor, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 5th Floor UCD Building, Daulby Street, Liverpool L69 3GA, United Kingdom. p.ghaneh@liverpool.ac.uk
Telephone: +44-151-7064170 Fax: +44-151-7065826
Received: February 26, 2014
Revised: April 29, 2014
Accepted: May 25, 2014
Published online: October 28, 2014
Processing time: 245 Days and 14.1 Hours
Revised: April 29, 2014
Accepted: May 25, 2014
Published online: October 28, 2014
Processing time: 245 Days and 14.1 Hours
Core Tip
Core tip: This paper discusses every major trial undertaken in the field of adjuvant therapy in pancreatic cancer. The evolution of chemotherapeutic regimes over the past 25 years and the controversy surrounding chemoradiation are analysed, in addition to looking at the phase III trials currently in progress.